OptiNose - Asset Resilience Ratio
OptiNose (OPTN) has an Asset Resilience Ratio of 0.01% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of OptiNose for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2017)
This chart shows how OptiNose's Asset Resilience Ratio has changed over time. See OPTN net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down OptiNose's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OptiNose (OPTN) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.00K | 0.01% |
| Total Liquid Assets | $15.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: OptiNose maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
OptiNose Industry Peers by Asset Resilience Ratio
Compare OptiNose's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089 |
Drug Manufacturers - Specialty & Generic | 10.89% |
|
KPC Pharmaceuticals Inc
SHG:600422 |
Drug Manufacturers - Specialty & Generic | 16.37% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117 |
Drug Manufacturers - Specialty & Generic | 3.51% |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566 |
Drug Manufacturers - Specialty & Generic | 5.72% |
Annual Asset Resilience Ratio for OptiNose (2017–2017)
The table below shows the annual Asset Resilience Ratio data for OptiNose.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $241.14 Million | -- |
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more